$RVVTF count down has started to FDA Covid19 request for EP End Point change for the EUA application/approval.
$9/share target may be conservative if approved and or there is a buy out by BP Big Pharma.
The drug #Bucillamine has been used safely for 30 years for RA, autoimmune disease and may end up being used for what is now rampant #LongHaulCovid19
The Dales Report @TheDalesReport $RVVTF AGM just finished. Some key takeaways:
- Revive has 450-500 patient data scrubbed/ready to present to regulators as needed - Capital raise possible if EP swap approved - FDA should have EP decision in 30 days - Clinical trial sites on standby if add-on patient data needed